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Heparan sulphate (glucosamine) 3-O-sulphotransferase 2 (HS3ST2, also known as 3OST2) is an enzyme predominantly expressed
in neurons wherein it generates rare 3-O-sulphated domains of unknown functions in heparan sulphates. In Alzheimer’s disease,
heparan sulphates accumulate at the intracellular level in disease neurons where they co-localize with the neuroﬁbrillary pathology,
while they persist at the neuronal cell membrane in normal brain. However, it is unknown whether HS3ST2 and its 3-O-sulphated
heparan sulphate products are involved in the mechanisms leading to the abnormal phosphorylation of tau in Alzheimer’s disease
and related tauopathies. Here, we ﬁrst measured the transcript levels of all human heparan sulphate sulphotransferases in hippo-
campus of Alzheimer’s disease (n = 8; 76.8  3.5 years old) and found increased expression of HS3ST2 (P50.001) compared with
control brain (n = 8; 67.8  2.9 years old). Then, to investigate whether the membrane-associated 3-O-sulphated heparan sulphates
translocate to the intracellular level under pathological conditions, we used two cell models of tauopathy in neuro-differentiated
SH-SY5Y cells: a tau mutation-dependent model in cells expressing human tau carrying the P301L mutation hTauP301L, and a tau
mutation-independent model in where tau hyperphosphorylation is induced by oxidative stress. Confocal microscopy, ﬂuorescence
resonance energy transfer, and western blot analyses showed that 3-O-sulphated heparan sulphates can be internalized into cells
where they interact with tau, promoting its abnormal phosphorylation, but not that of p38 or NF-B p65. We showed, in vitro,
that the 3-O-sulphated heparan sulphates bind to tau, but not to GSK3B, protein kinase A or protein phosphatase 2, inducing its
abnormal phosphorylation. Finally, we demonstrated in a zebraﬁsh model of tauopathy expressing the hTauP301L, that inhibiting
hs3st2 (also known as 3ost2) expression results in a strong inhibition of the abnormally phosphorylated tau epitopes in brain and
in spinal cord, leading to a complete recovery of motor neuronal axons length (n = 25; P5 0.005) and of the animal motor
response to touching stimuli (n = 150; P5 0.005). Our ﬁndings indicate that HS3ST2 centrally participates to the molecular
mechanisms leading the abnormal phosphorylation of tau. By interacting with tau at the intracellular level, the 3-O-sulphated
heparan sulphates produced by HS3ST2 might act as molecular chaperones allowing the abnormal phosphorylation of tau. We
propose HS3ST2 as a novel therapeutic target for Alzheimer’s disease.
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Introduction
Heparan sulphate (glucosamine) 3-O-sulphotransferase 2
(HS3ST2, also known as 3OST2) is an enzyme predomin-
antly expressed in brain (Shworak et al., 1999; Yabe et al.,
2005), where it generates rare 3-O-sulphated domains of
still unrevealed physiological roles in heparan sulphates
(Lawrence et al., 2007; Mochizuki et al., 2008; Thacker
et al., 2014). During adulthood, HS3ST2 is expressed in
brainstem, trigeminal ganglia (Lawrence et al., 2007), cere-
bral cortex (Mochizuki et al., 2008) and hippocampus
(Huynh et al., 2012), brain regions vulnerable to tau path-
ology in Alzheimer’s disease (Wenk, 2003; Braak and Del
Tredici, 2012). In contrast, it is almost absent in cerebellum
(Lawrence et al., 2007; Mochizuki et al., 2008; Thacker
et al., 2014), a brain region of low disease vulnerability
(Wu et al., 2005). Under physiological conditions heparan
sulphates are typically located at the cell surface (Kreuger
and Kjelle´n, 2012), whereas in Alzheimer’s disease they
accumulate at the intracellular level long before the detec-
tion of the tau pathology (Snow et al., 1990) and co-
localize with neuroﬁbrillary tangles when the pathology is
detected (Snow et al., 1990; Goedert et al., 1996;
Hernandez et al., 2002). This suggests the implication of
heparan sulphates in the pathophysiological mechanisms
leading to tauopathy. The abnormal hyperphosphorylation
of the microtubule-associated protein tau is a critical event
characterizing both sporadic and inherited tauopathies
(Iqbal et al. 2010; Wang et al., 2013), including
Alzheimer’s disease, Pick’s disease, progressive supranuclear
palsy, corticobasal degeneration, frontotemporal dementia
with parkinsonism linked to chromosome-17 (FTDP-17)
and related disorders (Williams, 2006; Spillantini and
Goedert, 2013). Interestingly, the abnormal phosphoryl-
ation of tau in the disease brain is assumed to be mediated
by the same kinases that phosphorylate tau in normal brain
(Hashiguchi and Hashiguchi, 2013; Wang et al., 2013);
however, in vitro, these kinases can only induce the abnor-
mal phosphorylation of tau at disease-speciﬁc sites only if
the enzymatic reaction takes place in the presence of poly-
anions such as heparin (Hasegawa et al., 1997; Zheng-
Fischhofer et al., 1998; Paudel and Li, 1999; Sibille et al.,
2006). Because heparin is a heparan sulphate analogue
carrying high levels of 3-O-sulphation in the sugar back-
bone (Kreuger and Kjelle´n, 2012; Shriver et al., 2012), this
raises the question whether 3-O-sulphated heparan sul-
phates, products of neuronal 3-O-sulphotransferases, are
involved in the molecular and cellular mechanisms leading
to the abnormal phosphorylation of tau. Here, we used
biochemical, cellular, and animal strategies to investigate
the implication of HS3ST2 in the molecular and cellular
mechanisms leading to the abnormal phosphorylation of
both wild-type tau and of tau carrying the mutation
P301L (hTauP301L) responsible of FTDP-17 (Alonso Adel
et al., 2004; Williams, 2006). We show that the chemical
inhibition of heparan sulphate sulphation, or the down-
regulation of HS3ST2 expression in cells, strongly avoids
the hyperphosphorylation of tau induced by oxidative
stress or by the hTauP301L mutation, and that inhibiting
the expression of hs3st2 in a FTDP-17 zebraﬁsh model of
tauopathy (Paquet et al., 2009) avoids the abnormal phos-
phorylation of tau at several Alzheimer’s disease-related
epitopes resulting in tauopathy arrest and animal func-
tional recovery.
Materials and methods
Human tissues
Human hippocampus samples were obtained from the Aging
and Neurodegenerative Diseases Brain Bank Investigation
Laboratory of the Universidade Federal de Sa˜o Paulo, Brazil.
Protocols were approved by the local ethics committee
(No.285/04). Two experimental groups were included in the
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study (Supplementary Table 1), a control group (n = 8) and an
Alzheimer’s disease group (n = 8) with subjects’ ages ranging
from 60 to 98 years old with a mean age of 73.4  10.7 years.
Post-mortem intervals averaged 14 h 59min  5h 41min.
Neuropathological changes in brains were investigated using
Braak and Braak and Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) guidelines. Senile plaques and
neuroﬁbrillary tangles were determined on Bielschowsky-
stained sections of middle frontal gyrus, middle temporal
gyrus, inferior parietal lobule, occipital pole, hippocampal
CA1 and enthorinal cortex. Senile plaques were counted
using a 10 objective and neuroﬁbrillary tangles were counted
with a 20 objective. An arithmetic mean (mean  standard
error of the mean) was calculated from the counts of six ﬁelds
for senile plaques by mm2 and neuroﬁbrillary tangles by mm2
for each region. Neuropathological diagnosis was then made
using the guidelines proposed by Braak and Braak criteria
(Supplementary Table 1). Brain samples were powdered in
liquid nitrogen and stored at 80C until use.
Quantitative polymerase chain
reaction
Total RNA was extracted from frozen hippocampus CA1 sam-
ples as described (Huynh et al., 2012). The amount of RNA in
the extracts was measured spectrophotometrically at 260 and
280nm. The quality of RNA was conﬁrmed suitable deter-
mined by gel electrophoresis. RNA quality was additionally
conﬁrmed by RIN (RNA integrity number) determination
(Schroeder et al., 2006) obtained by the ‘Standardization of
RNA Quality Control Protocol’ in a 2100 Bioanalyzer
(Agilent). RIN average was 47.0 for all samples. Extracted
RNA was used to synthesize cDNA using reverse transcriptase
as previously reported (Huynh et al., 2012). Genes of interest
were analysed in template cDNA by quantitative real-time
PCR using primers (Euroﬁns) designed by the Primer3output
program. PCR was performed according to the LightCycler
FastStart DNA Master SYBR Green kit manufacturer’s in-
structions (Roche). Relative gene expression quantiﬁcation
was performed using the comparative CT method (Schefe
et al., 2006). Two reference genes (TUBA1A and TBP) were
used as endogenous controls. Normalization of gene expres-
sion was accomplished with the Genorm program
(Vandesompele et al., 2002).
Cells models of tauopathy
SH-SY5Y and SH-SY5Y/hTauP301L (SH/hTauP301L) cells (a gift
from J. Gotz, Zu¨rich, Switzerland) were maintained and cul-
tured as previously described (Ferrari et al., 2003). Brieﬂy, SH-
SY5Y cells were grown in DMEM-GlutaMAXTM (Invitrogen)
supplemented with 10% foetal bovine serum (Invitrogen) and
1% penicillin/streptomycin (Invitrogen). For SH-SY5Y/
hTauP301L cells, 300mg/ml geneticin (Invitrogen) and pyruvate
were added to the medium. For all experiments, cells were
differentiated 24 h after plating by treatment with 10 mM all-
trans-retinoic acid (Sigma) in complete growth medium for 7
days. Media were changed every 2 days. For oxidative stress
studies, differentiated SH-SY5Y cells were treated with H2O2
(500mM ﬁnal concentration in medium) for 30min as previ-
ously described (Zhang et al., 2013). In assays involving
NaClO3 (Keller et al., 2008), the salt was added to cell cul-
tures (25, 50 or 75mM ﬁnal concentration) at the third or ﬁfth
day of differentiation, as indicated, and maintained until the
end of the experiment. For enzymatic treatments, differentiated
cells were treated either with a heparitinase mix containing
heparitinase I (2 U/ml), heparitinase II (0.2 U/ml), and hepar-
itinase III (0.2 U/ml) (all from Sigma), or with chondroitinase
ABC (0.1 U/ml) (Sigma) and incubated at 37C for 1.5 or 6 h
(as indicated). After enzymatic treatment, medium was chan-
ged for new fresh medium and cells were subjected to the
speciﬁed corresponding experimental conditions.
Cell transfections, plasmids and
lentivirus
Two lentiviral vectors pTrip-CMV-Egfp-miRNA-HS3ST2 de-
signed to inhibit HS3ST2 expression were purchased from
the vectorology platform of the Brain and Spinal
Cord Institute (Paris, France). Brieﬂy, four plasmids containing
different miRNAs targeting the HS3ST2 gene coding sequence
were designed with the following sequences: dsOligo-miRNA1:
50-TGCTGCCTTCTTCACGCCCACAATGAGTTTTGGCCA
CTGACTGACTCATTGTGCGTCAAGAAAG-30, 30-CGGAA
GAAGTGCGGGTGTTACTCAAAACCGGTGACTGACTGA
GTAACACGCAGTTCTTTCGTCC-50; dsOligo-miRNA2:
50-TGCTGGACTCGCCCCATCTCGCCGGCGTTTTGGCCA
CTGACTGACGCTGGTGATGGGTCGTATT-30, 30-CCTG
AGCGGGGTAGAGCGGCCGCAAAACCGGTGACTGACTG
CGACCACTACCCAGCATAAGTCC-50. A sequence of the
GFP was also introduced in the vector for monitoring simul-
taneous expression. The lentiviral vector pTrip-CMV-eGFP-
miRneg was used as control. For silencing experiments, SH/
hTauP301L cells (300 000) were suspended and transduced with
a 1:20 dilution of a concentrated suspension of the two lenti-
viral vectors mixture containing 0.1  109 physical particles/ml.
Cells were then plated in 24-well plates (Nunc) and incubated
for 72 h under standard conditions. Cell lysates were immuno-
blotted as speciﬁed above with antibodies directed to HS3ST2,
pSer396, Tau-5, and anti-b-actin (Life Technologies).
Immunofluorescence
For immunoﬂuorescence studies, cells were plated in 35-mm
Petri dishes (m-Dish, Ibidi) at a density of 40 000 cells/dish
following manufacturer’s instructions. Differentiation, stress
and any other treatments were performed as described above.
For analysis, cells were washed, ﬁxed in 100% methanol at
20C and washed again before been incubated with 2%
donkey serum in phosphate-buffered saline (PBS) for 20min
at room temperature. Cells were then incubated for 1 h with
the corresponding primary antibody at room temperature,
washed and incubated with the appropriate secondary anti-
body for 30min at room temperature. The antibodies used
were HS4C3 (Tem Dam et al., 2006) (TH v Kuppevelt is
author of the work; 1:100), tau K9JA (Dako; 1:500) or tau
V-20 (Santa Cruz; 1:100). Secondary antibodies were Fluo488
donkey anti-rabbit (Interchim; 1:200), Fluo488 donkey anti-
goat (Interchim; 1:200), and Cy3 goat anti-mouse (Sigma;
1:200). The phage display HS4C3 antibody was revealed by
an anti-VSV antibody (Sigma; 1:100). Stack images were ob-
tained with the software CellSens from a spinning disk
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inverted confocal microscope (IX81 DSU Olympus, 60N.A.
1.35) coupled to an Orca Hamamatsu RCCD camera. Images
were processed with the ImageJ software (W. Rasband,
National Institute of Health).
Western blotting
For protein analysis by western blot, powdered frozen tissue or
cells were suspended (100mg of tissue/ml or 1.8  105 cells/
ml) in an extraction buffer (50mM Tris-HCl, 150mM NaCl,
1% TritonTM X-100, 10mM NaF, 1mM Na3VO4, pH 8.0)
supplemented with protease and phosphatase inhibitors
(Pierce). Tissue homogenates were centrifuged at 12 000 g for
15min and the protein content in the supernatants was deter-
mined using BCA Protein Assay kit (Pierce). Samples contain-
ing 20 mg proteins were subjected to SDS-PAGE in 10%
acrylamide gel. Primary antibodies for phosphorylated tau
were pSer199, pSer199/pSer202, pThr231, pSer262, pSer396
(Life Technologies), AT8, AT270, PHF1, AT180, AT100
(Pierce, Thermo Scientiﬁc), and MC1 (a gift from Peter
Davies); anti-total tau antibody was Tau-5 (Millipore). Other
antibodies used were against HS3ST2, HS3ST4 (Clinisciences),
p38, pp38, NF-B p65, pNF-B p65 (Cell Signaling technol-
ogy), and anti-b-actin (Life Technologies). Corresponding sec-
ondary antibodies diluted in phosphate-buffered saline
containing 1% milk were incubated for 1 h at room tempera-
ture. Blots were developed either with Immobilon Western
Chemiluminiscent HRP Substrate, Luminata Forte, Luminata
Crescendo (Millipore), or SuperSignal West Dura (Thermo
Scientiﬁc) following manufacturer’s instructions.
Densitometric quantiﬁcation of immunoreactivity was per-
formed by using the ImageJ software. Hyperphosphorylated
tau signals were normalized to total tau detected with the
anti-Tau-5 antibody. b-Actin was used to standardize total
protein load.
Fluorescence resonance energy
transfer assay
Fluorescence resonance energy transfer (FRET) assays were
performed as in Li et al. (2012) by using a cryptate-d2
system (CISBIO Bioassays). Brieﬂy, cell lysates (10 ml at
2.6 mg/ml of protein) were mixed with HS4C3 antibody in
384-well plates and incubated for 20min at room temperature.
Next, cryptate-conjugated anti-VSV and d2-conjugated anti-
tau K9JA were added to the reaction mixture following the
manufacturer’s instructions. After 20min of incubation, energy
transfer was measured using a TECAN Inﬁnite 1000 spec-
trometer, data were processed according to manufacturer’s
instructions.
Tau and tauP301L phosphorylation
assay
Tau phosphorylation reactions were carried out according to
Hasegawa et al. (1997) with some modiﬁcations. Brieﬂy, four
different solutions containing tau at 200mg/ml, GSK3B
(Promega) at 20 mg/ml, respectively, heparin (Sigma) at 60 mg/
ml, and ATP at 250mM, were prepared in a reaction buffer
(40mM Tris-HCl, 20mM MgCl2, 0.1mg/ml BSA, pH 7.5).
The four solutions were mixed, and when necessary diluted
in reaction buffer, to set reaction mixtures containing 1 mg of
the tau substrate, 100 ng of the enzyme, and 50 mM ATP, in
the presence or absence of 0.3 mg heparin (20 ml ﬁnal reaction
volume). When indicated, protein kinase A (PKA) (Sigma) was
included in the reaction mixture at 3 mg/ml ﬁnal concentration.
Tau was either full-length recombinant human tau (Millipore)
or full-length recombinant tauP301L (Interchim). The amount of
tau, GSK3B and PKA used in the reactions was selected from
dose response experiments with 0.5, 1.0, or 2.0mg of tau and
50, 100, or 200ng of enzyme. Reactions were carried out at
30C for 3h and stopped by cooling at 20C. Reaction mix-
tures were resolved by western blot as described above, with
one or several of the following antibodies: pSer396, pSer199/
202, AT270, PHF1, AT8, AT100, and MC1.
Kinase and phosphatase activities
The effect of heparin on the kinase and phosphatase enzymatic
activities was assessed with kits for GSK3B (Promega), protein
phosphatase 2A (PP2A, Promega), and PA (Abcam) by follow-
ing the manufacturer’s instructions. The enzymatic reactions
were performed in the absence or presence of heparin at sev-
eral concentrations (from 0.1 ng/ml to 100mg/ml).
Enzyme-linked immunosorbent
assays
Binding of tau, tauP301L, GSK3B, PKA, or PP2A to heparin
was evaluated by ELISA as in Huynh et al. (2012). Brieﬂy,
ELISA-type 96-well plates were coated with a 2mg/ml bovine
serum albumin (BSA) heparin conjugate solution. After wash-
ing the wells with PBS containing 0.05% Tween-20, wells were
saturated with 3% BSA in PBS. Then, the tested protein (full
length human tau, tauP301L, GSK3B, PKA or PP2A) was added
to the plate at various concentrations and plates were incu-
bated for 12 h at 4C. After washing, the protein bond to
heparin was revealed by the corresponding speciﬁc antibody
Tau-5, anti-GSK3B (Thermoﬁsher), anti-PKA, or anti-PP2A
(Sigma) followed by a peroxidase-labelled secondary antibody.
Peroxidase activity was measured by the TMB detection kit
(Pierce) following fabricant instructions. For the ELISA com-
petition assays, heparin or heparan sulphate were added to the
wells at concentrations ranging from 0.01 ng/ml to 10 mg/ml
following addition of the corresponding protein (tau,
tauP301L, GSK3B, PKA, or PP2A) to the wells.
Zebrafish
Zebraﬁsh were maintained in a standard zebraﬁsh facility
(Aquatic Habitats, Apopka). Developmental stages were deter-
mined as hours post fertilization (hpf) or as days post fertil-
ization (dpf), as previously described (Kimmel et al., 1995).
Wild-type embryos were from the AB and TL strains. The
Tg[HuC::hTauP301L;DsRed] transgenic line has been previously
described (Paquet et al., 2009). All procedures involving
animal handling complied with the guidelines of the French
Animal Ethics Committee and were approved by the same
committee under the ethics statement N: 2012-15/676-0069.
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Morpholino oligonucleotides
Morpholinos MO-HS3ST2AUG: 50-GGCTTGACAGGAACCT
ATATGCCAT-30, MO-HS3ST2SPL: 50-AAAATTAACCTTAC
CTGTACCAGTC-30 and mmMO-HS3ST2AUG: 50-GGCTTG
ACATGAAGATATATGGTAT-30, were obtained from Gene
Tools. For morpholino-mediated zebraﬁsh hs3st2 transcript in-
activation, 2 nl of a 1.5mM solution, corresponding to 3 pmol
of each morpholino were injected in 1- to 2-cell stage embryos
using standard protocols. Antibodies directed against patho-
logic tau epitopes were AT180, MC1 and AT270. AT8 and
PHF1 for zebraﬁsh experiments were kindly provided by
D. Paquet. Anti-human tau antibody was purchased from
DakoCytomation. Primary motor neuron morphology was
analysed using the mouse monoclonal anti-synaptotagmin 1
antibody (anti-Syt1; 1/300, Hybridoma Bank).
Analysis of zebrafish behaviour
Touch-induced escape response was assessed by gently touch-
ing the tail of embryos with the tip of a ﬁne plastic rod (Paquet
et al., 2009). Embryos were then classiﬁed as responders or
non-responders.
Statistical analyses
All data are expressed as the mean  standard error of the
mean (SEM) or standard deviation (SD) as speciﬁed. P-values
were generated using non-parametric t-test, Mann Whitney U-
test, or ANOVA, as speciﬁed. Asterisks indicate signiﬁcant dif-
ferences (*P50.05, **P5 0.005, ***P50.001); n.s. indi-
cates non-signiﬁcant differences.
Results
HS3ST2 is overexpressed in
Alzheimer’s disease brain
In a previous work, we showed that HS3ST1, HS3ST2,
HS3ST3A, HS3ST3B, HS3ST4, and HS3ST5 are expressed
in human elderly hippocampus (Huynh et al., 2012).
However, it is unknown whether the expression of these
enzymes is altered in brain of Alzheimer’s disease. To ﬁrst
investigate this possibility, we compared the transcript
levels of all human sulphotransferases (Kreuger and
Kjelle´n, 2012) from Alzheimer’s disease hippocampus
(CA1) to those from age-matched controls. We used quan-
titative PCR to determine levels of mRNA encoding for the
four heparan sulphate N-deacetylase/N-sulphotransferases
(NDST1, NDST2, NDST3 and NDST4) and for the differ-
ent sulphotransferases including HS2ST, HS3STs (1, 2, 3A,
3B, 4, 5, and 6), and HS6STs (1, 2 mRNA variants 2L and
2S, and 3), as well as C-5 epimerase (GLCE) and HPSE
(heparanase), two other enzymes implicated in heparan sul-
phate metabolism. Among the 18 analysed transcripts, ex-
pression levels of most sulphotransferases were slightly
(P50.05) increased in the Alzheimer’s brains compared
to age-matched-individuals. However, only HS3ST2 and
HS3ST4 were expressed at higher signiﬁcant levels
(P5 0.001), as analysed by the Mann Whitney U-test
(Table 1). Remarkably, western blot analysis of the hippo-
campal protein extracts showed a higher HS3ST2 expres-
sion, compared to HS3ST4, in the Alzheimer’s tissue
(Supplementary Fig. 1). This suggests that in Alzheimer’s
disease, 3-O-sulphated domains in heparan sulphates are
increased in brain regions in where these enzymes are ex-
pressed (Lawrence et al., 2007; Mochizuki et al., 2008).
3-O-sulphated heparan sulphates
interact with tau in cell models of
tauopathy
In Alzheimer’s disease, heparan sulphates accumulate in the
intracellular space of neurons before the apparition of the
tau pathology (Snow et al., 1990) and strongly co-stain
with tau in intracellular neuroﬁbrillary tangles during dis-
ease (Snow et al., 1990; Goedert et al., 1996; Hernandez
et al., 2002). However, under physiological conditions,
these sulphated polysaccharides are located at the extracel-
lular space, in where they exert their known biological
functions (Kreuger and Kjelle´n, 2012; Thacker et al.,
2014). Thus, we ﬁrst thought to investigate whether 3-O-
sulphated heparan sulphate internalization and interaction
with tau can be provoked under tauopathy-associated
Table 1 Expression of heparan sulphate metabolic
enzyme mRNA in hippocampus from control and
Alzheimer’s disease
Enzymes Isoforms Control group AD group
(AU  SD)
NDST1 0.33  0.06 0.38  0.06
NDST2 0.59  0.38 1.38  0.42*
NDST3 n.d. n.d.
NDST4 n.d. n.d.
HS2ST 0.89  0.07 1.03  0.13*
HS3ST1 0.75  0.09 0.96  0.20
HS3ST2 0.37  0.07 2.06  0.39***
HS3ST3A1 0.35  0.08 2.17  1.69*
HS3ST3B1 0.58  0.21 1.76  0.90*
HS3ST4 1.33  0.35 5.04  0.34***
HS3ST5 0.10  0.04 0.08  0.02
HS3ST6 n.d. n.d.
HS6ST1 0.45  0.57 1.35  0.77*
HS6ST2(var L) 0.35  0.30 1.06  0.55*
HS6ST2(var S) 0.47  0.48 0.64  0.22
HS6ST3 2.41  0.77 2.96  0.82
GLCE 0.35  0.21 1.13  0.62*
HPSE 0.23  0.03 0.38  0.06*
GLUL 0.49  0.08 1.23  0.18**
CXCR4 0.73  0.26 0.68  0.14
*Significant changes in transcript expression as defined by the Mann Whitney U-test
(n = 8).
n.d. = the transcript was not detected.
AU  SD = arbitrary units  SD.
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conditions, such as oxidative stress or expression of a
pathologic tau mutation. We used two cell models: (i) an
oxidative stress (SH/ox) model in wild-type SH-SY5Y cells
(Zhang et al., 2013); and (ii) a tau-mutation-dependent
model in SH-SY5Y cells overexpressing the hTauP301L
mutant (SH/hTauP301L) (Ferrari et al., 2003), which under-
lies FTDP-17 (Alonso Adel et al., 2004). By using a 3-O-
sulphated heparan sulphate speciﬁc antibody (HS4C3) (Ten
Dam et al., 2006), we conﬁrmed by confocal microscopy
that the sulphated polysaccharide accumulates at the cell
surface in wild-type and control cells (Fig. 1A and C, and
Supplementary Fig. 2), whereas a strong intracellular
immunostaining was observed in both SH/ox (Fig. 1B and
Supplementary Fig. 3) and SH/hTauP301L cells (Fig. 1D and
Supplementary Fig. 4A). In SH/ox cells we observed a
strong 3-O-sulphated heparan sulphate staining near the
cell membrane at 10min after the stress pulse
(Supplementary Fig. 3A), whereas at 6 h after stress the
membrane staining was strongly decreased and highly pro-
nounced at the intracellular space (Supplementary Fig. 3B),
suggesting a stress-driven time course internalization of the
membrane-associated polysaccharides. In contrast, in
SH/hTauP301L cells, the 3-O-sulphated polysaccharide was
permanently and highly accumulated in the form of intra-
cellular inclusions showing different levels of overlap with
tau (Supplementary Fig. 4A), but nearly absent at the cell
membrane. No differences in the level or distribution of
chondroitin sulphates were observed in either of the cell
models (not shown).
The accumulation of intracellular 3-O-sulphated heparan
sulphates in both SH/ox and SH/hTauP301L cells raised the
question whether these sulphated polysaccharides were of
membrane origin. To address this issue, we cultured SH/ox
and SH/hTauP301L cells in the presence of a mixture of
heparitinase I, II and III, an enzymatic cocktail that digests
the heparan sulphate glycanic chains of membrane-bound
heparan sulphate proteoglycan (HSPG). As expected, the
heparitinases treatment strongly decreased the staining of
membrane-associated heparan sulphate in control cells
(Fig. 2A), and, surprisingly, nearly suppressed the staining
of the intracellular heparan sulphate inclusions in the two
cell models (Fig. 2B–D and Supplementary Fig. 4B), suggest-
ing that the intracellular 3-O-sulphated heparan sulphates
observed in both SH/ox and SH/TauP301L cells existed as
HSPG in cell membranes before being internalized within
the cells. As confocal microscopy co-localization cannot be
Figure 1 Intracellular 3-O-sulphated heparan sulphates and tau co-staining in two cell models of tauopathy. (A) Immunostaining
of cell membrane-associated 3-O-sulphated heparan sulphates (red) and intracellular tau (green) in control cells (optical section). (B) 3-O-
sulphated heparan sulphate immunostaining increases in cell membranes early after stress to then decrease in a time dependent manner with
concomitant increase of intracellular staining. (C) Empty vector (EV) transfected cells. (D) Intracellular 3-O-sulphated heparan sulphate inclusions
accumulate and co-stain with tau at different extents in SH/hTauP301L cells. Pictures represent observations on cells from three independent
experiments. Scale bars = 10mm.
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considered as an evidence of molecular interactions, we fur-
ther investigated whether the 3-O-sulphated heparan sul-
phates interact with tau at the molecular level by
performing FRET experiments (Li et al., 2012) in SH/ox
cells. We incubated cell lysates with a europium-labelled sec-
ondary antibody directed against the HS4C3 antibody and a
d2-labelled anti-tau primary antibody. The FRET signal
observed in the stressed cells as early as 10min and at 6 h
after the stress pulse was nearly abolished when cells were
cultured in the presence of heparitinase (Fig. 2E), but not of
chondroitinase (not shown), indicating a close interaction of
3-O-sulphated heparan sulphates with tau.
To investigate the importance of 3-O-sulphates in the
interaction of heparan sulphates with tau, we performed
an ELISA-based competition essay to compare the capacity
of tau to bind to highly 3-O-sulphated heparan sulphates,
here represented by heparin, compared to less sulphated
heparan sulphates (Shriver et al., 2012). As expected, we
Figure 2 3-O-sulphated heparan sulphates interact with tau under pathological conditions. Heparitinase (Hep-ase) treatment
decreases membrane-associated and intracellular 3-O-sulphated heparan sulphates (red) staining and co-localization with tau. Z-projections are
depicted for (A) control cells; (B) SH/ox cells treated with heparitinase before the oxidative stress pulse; and (C) SH/hTauP301L cells.
(D) Quantification of heparan sulphates (HS) intracellular inclusions in SH/hTauP301L cells treated with hep-ase during 1.5 or 6 h. (E) FRET-based
measurement of the molecular interaction between 3-O-sulphated heparan sulphates and tau in SH/ox cell lysates at different time points after the
stress pulse. Calculated delta F (F) shows a time-dependent molecular interaction abolished when cells were cultured in the presence of
heparitinase I, II, III cocktail (Hep-ase). (F) ELISA competition assay showing the higher capacity of heparin, used as a prototype of 3-O-sulphate
heparan sulphates, to inhibit the binding of tau to immobilized heparin compared to heparan sulphates. Data represents the mean of three
different experiments performed in triplicate each time; error bars show SEM.
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observed that tau binds to heparin better than to
heparan sulphates (Fig. 2F), suggesting that increasing
3-O-sulphation levels in heparan sulphate could result in
heparan sulphate increased capacity to interact with tau.
Together, these results suggest that under pathological con-
ditions, 3-O-sulphated heparan sulphates can interact with
tau inside cells in where they could participate to the cel-
lular mechanisms inducing the pathological phosphoryl-
ation of the protein.
Pathological phosphorylation of tau
requires 3-O-sulphated heparan
sulphates
In an attempt to understand the role of the 3-O-sulphated
heparan sulphates in the abnormal hyperphosphorylation
of tau, we sought to investigate whether these polysacchar-
ides are required for tau hyperphosphorylation in both
SH/ox and SH/hTauP301L cells. As western blot analysis
using the Tau-5 antibody showed a higher level of total
tau in the SH/hTauP301L cells compared to SH/ox cells
(Supplementary Fig. 5A), all phosphorylated tau levels
were further normalized against total tau (Tau-5). First,
we conﬁrmed that, compared to control cells, SH/ox and
SH/hTauP301L cells accumulate higher levels of tau phos-
phorylated at Ser199 (pSer199), Thr231 (pThr231),
Ser262 (pSer262), and Ser396 (pSer396), characteristic
hyperphosphorylated residues in Alzheimer’s disease
(Steinhilb et al., 2007; Duka et al., 2013). In the SH/ox
cells, maximum pSer199, pThr231, and pSer262 levels
were observed 10min after the stress pulse, while max-
imum pSer396 was detected 6 h later (Supplementary Fig.
5B). To investigate whether heparan sulphates are required
for tau hyperphosphorylation at these sites, we treated cells
with sodium chlorate (NaClO3), an inhibitor of the synthe-
sis of PAPS (30-phosphoadenosine 50-phosphosulphate), the
sulphate donor in glycosaminoglycan biosynthesis
(Venkatachalam, 2003). High NaClO3 concentrations
have shown to inhibit the formation of highly sulphated
heparan sulphates under classic cell culture conditions
(Safaiyan et al., 1999; Keller et al., 2008). Here, following
treatment with NaClO3, we observed a signiﬁcant decrease
in hyperphosphorylated tau accumulation, notably in SH/
ox cells (Fig. 3A). Although this decrease was less promin-
ently in SH/hTauP301L cells (Fig. 3B), which required higher
NaClO3 concentrations, this suggests the involvement of
sulphated glycosaminoglycans in the hyperphosphorylation
event. To determine which glycosaminoglycan species are
involved in this process, we incubated SH/ox and
SH/TauP301L cells with either chondroitinase ABC or hepar-
itinase. While heparitinase digestion signiﬁcantly decreased
the accumulation of hyperphosphorylated tau in both SH/
ox and SH/TauP301L cells (Fig. 3C–E), chondroitinase treat-
ment showed no effect (Fig. 3C and D), indicating that
highly sulphated heparan sulphates, but not chondroitin
sulphates, are required for tau hyperphosphorylation in
both cell models. To investigate whether inhibiting the cel-
lular heparan sulphates can affect the phosphorylation of
other cytosolic proteins, we evaluated the phosphorylation
of the subunit p65 of NF-B and of p38 in both models.
No differences in the phosphorylation of these proteins
were observed (Fig. 3F). This result, as well as the 3-O-
sulphated heparan sulphates interaction with tau observed
by FRET, suggests a speciﬁc effect of 3-O-sulphated
heparan sulphates on tau. However, this effect could also
be driven by altered kinases or phosphatases activities
through indirect mechanisms that should be further studied.
Thus, by using an ELISA assay, we compared the capacities
of tau, tauP301L, GSK3B, PKA and PP2A, to bind to immo-
bilized heparin as a prototype of 3-O-sulphated heparan
sulphates. Our results show that tau and tauP301L, but
not GSK3B, PKA, and PP2A, could efﬁciently bind to the
sulphated polysaccharide (Fig. 3G).
Together, our results suggest that highly sulphated
heparan sulphates favour the abnormal phosphorylation
of tau in cells in where 3-O-sulphated heparan sulphates
interact with tau. To examine if 3-O-sulphated heparan
sulphates directly participate to the abnormal phosphoryl-
ation of wild-type tau, we used an in vitro GSK3B-depend-
ent tau phosphorylation reaction and examined the
occurrence of phosphorylation at residues Thr181
(AT270 antibody), Ser396/Ser404 (PHF1 antibody),
Ser202/Thr205 (AT8 antibody), Ser212/Ser214 (AT100),
and the conformational anti-tau MC1 antibody, speciﬁc
of Alzheimer’s disease and other tauopathies (Cripps
et al., 2006; Yoshida and Goedert 2006; Steinhilb et al.,
2007; Duka et al., 2013). We observed that the GSK3B-
dependent phosphorylation at AT270, PHF1, and AT8
epitopes requires the presence of heparin in the reaction
mixture (Fig. 4A). Interestingly, the effect of heparin at
the AT100 epitope required the introduction of PKA into
the GSK3B reaction mixture. Under these conditions, we
observed that the abnormal phosphorylation of tau at the
AT100 epitope is also heparin dependent (Fig. 4B).
However, when we used the MC1 antibody, no differences
were observed in western blots of reactions performed in
the presence or absence of heparin with and without add-
ition of PKA (not shown). This can be possibly due to a
blotting condition-dependent loss of the tau conformation
required for recognition of tau by this antibody, most
classically used for histological applications. We then ana-
lysed the effect of heparin in the GSK3B-dependent phos-
phorylation of tau at sites Ser396 and Ser199/202, found
phosphorylated at some extent in normal brain but hyper-
phosphorylated in case of tauopathy. We observed an
increased level of phosphorylation at these sites in reactions
carried out in the presence of heparin (Fig. 4C). We then
carried out the phosphorylation reaction using tauP301L in-
stead of the wild-type tau as substrate of the phosphoryl-
ation reaction. Heparin favoured the tauP301L abnormal
phosphorylation (Fig. 4D), in agreement with the role of
heparan sulphates in the abnormal phosphorylation of tau
in the HS/hTauP301L model of tauopathy. Interestingly,
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Figure 3 Sulphated heparan sulphates are required for tau hyperphosphorylation in two cell models of tauopathy. Tau hyper-
phosphorylated at Ser199, Thr231, Ser262, and Ser396, total tau (Tau-5), and b-actin levels in cells treated with NaClO3 in (A) SH/ox cells, and in
(B) SH/hTauP301L cells. (C) Hyperphosphorylated tau at Ser199 and Ser396 in SH/hTauP301L cells treated or not with heparitinases I, II, and III
cocktail (Hep-ase) or chondroitinase ABC (Cse). (D) Tau hyperphosphorylated at Ser199 in SH/ox cells after a stress pulse treated or not with
heparitinase, Cse or NaClO3. (E) Tau hyperphosphorylated at Ser396 in SH/ox cells treated or not with heparitinase prior to the oxidative stress
pulse. Data represent the mean of three different experiments performed in duplicate each time; error bars show SEM. (F) Western blots
showing the phosphorylation of NF-kB p65 and p38 proteins in SH/ox (left) and in SH/hTauP301L (right) cells treated or not with the heparitinases
cocktail or with NaClO3. Total levels of each protein, as well as that of b-actin, were used as loading controls. (G) ELISA assay showing the binding
of heparin to tau (filled circles, solid line), TauP301L (open circles, dashed line), GSK3B (upward triangles, spotted line), PP2A (downward triangles,
spotted line), and PKA (diamonds, solid line). Data in histograms were made from the average signal obtained from the densitometric analysis of
duplicates carried in each individual western blot, or by the average of two different western blots when duplicates were not performed.
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phosphorylation reaction showed to be more efﬁcient for
tauP301L than for wild-type tau, suggesting a higher suscep-
tibility to tau pathology when the mutation is present.
Our results suggest that implication of heparan sulphates
in the abnormal phosphorylation reaction is mediated by
their direct interaction with tau, and less probably by their
direct interaction with kinases or phosphatases (Fig. 3F and
G). To reinforce this hypothesis, we investigated if heparin
can modulate the enzymatic activity of GSK3B, PP2A, and
AP in vitro. By using commercial kits we measured the
activity of these enzymes and found that the addition of
heparin at various concentrations has no modulatory effect
in any of the tested enzymes (not shown), weakening the
assumption of a putative role of the sulphated polysacchar-
ides as kinase activators or phosphatase inhibitors.
Nevertheless, it remains to be explored if the activities of
kinases and phosphatases are altered in cells by mechan-
isms independent of their direct interaction with the
sulphated sugars.
Together, the in vitro and the intracellular interaction of
tau with heparin or heparan sulphates, as well as the effect
of these interactions on the abnormal phosphorylation of
tau, support the idea that intracellular 3-O-sulphated
heparan sulphates could display a tau-chaperone activity
critical for the abnormal phosphorylation of tau observed
under pathological conditions. However, the implication of
the speciﬁc 3-O-sulphation of heparan sulphates remains
unclear. To explore this possibility, we investigated the
effect of speciﬁcally silencing HS3ST2 expression in patho-
logical tau phosphorylation in SH/hTauP301L cells. We used
lentiviral vectors carrying miRNA designed to suppress
HS3ST2 expression. Cells were transfected and monitored
for pSer396 as a marker of tau hyperphosphorylation.
Inhibition of HS3ST2 expression resulted in a strong de-
crease of pSer396 accumulation (Fig. 4E), supporting the
implication of 3-O-sulphated heparan sulphates in the tau
phosphorylation event.
HS3ST2 is critical for the abnormal
phosphorylation of tau in vivo
We then investigated whether HS3ST2 is critical for abnor-
mal phosphorylation of tau in vivo. To address this issue,
we used the Tg[HuC::hTauP301L;DsRed] zebraﬁsh trans-
genic line (Paquet et al., 2009) and morpholino-mediated
inactivation of the zebraﬁsh hs3st2. Tg[HuC::
hTauP301L;DsRed] transgenic embryos express the human
mutant TauP301L protein under the control of the pan-neur-
onal HuC promoter and reproduce several characteristic
features of tauopathies, including an increased accumula-
tion of hyperphosphorylated tau in brain and spinal cord
neurons, neuronal abnormalities, neuronal death and im-
paired motility (Paquet et al., 2009). As expected, we de-
tected high levels of abnormally phosphorylated tau in a
large number of neurons scattered in several brain regions
of 5 dpf Tg[HuC::hTauP301L;DsRed] larvae (n = 100)
(Supplementary Fig. 6). By BLAST analysis of the Zv9
version of the zebraﬁsh genome sequence, we identiﬁed
a single hs3st2 gene in this species (ENSDARG000000
59616). We conﬁrmed that zebraﬁsh hs3st2 is composed
of two exons separated by a 452 kb intron, allowing the
synthesis of both translation- and splice-blocking morpho-
linos, which are referred to below as MO-hs3st2AUG and
MO-hs3st2SLP, respectively (Supplementary Fig. 7A). RT-
PCR analysis demonstrated efﬁcient zebraﬁsh hs3st2 spli-
cing inhibition in Tg[HuC::hTauP301L;DsRed] embryos
after injection of 1.5mM MO-hs3st2SPL (Supplementary
Fig. 7B). As control, we used a ﬁve mismatch-containing
derivative of MO-hs3st2AUG (mmMO-hs3st2AUG).
Tg[HuC::hTauP301L;DsRed] embryos injected with 1.5mM
MO-hs3st2SPL (n = 250) or MO-hs3st2AUG (n = 250) did
not show increased lethality or any visible phenotype
including developmental delay when compared to non-in-
jected controls or embryos that received 1.5mM mmMO-
hs3st2AUG (n = 250) (Supplementary Fig. 7C and D). We
Figure 4 Phosphorylation of tau and tauP301L at disease-
related sites is induced by heparin in vitro and by 3-O-
sulphated heparan sulphates in vitro and in cells. (A–C)
GSK3B-mediated abnormal phosphorylation of wild-type tau and
tauP301L is dependent on the presence of heparin in the reaction
mixture. (A) GSK3B-mediated abnormal phosphorylation of tau
at AT270, PHF1 and AT8. (B) GSK3B/PKA-mediated abnormal
phosphorylation of tau at the AT100 site. (C) GSK3B-mediated tau
hyperphosphorylation at sites pSer396 and pSer199/202.
(D) GSK3B-mediated abnormal phosphorylation of tau and tauP301L
at epitopes AT270 and PHF1. (E) Lentiviral vector miR-HS3ST2-
mediated down regulation of HS3ST2 shows a decreased accumu-
lation of hyperphosphorylated tau in SH/hTauP301L cells. All
experiments were performed at least three times.
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then quantiﬁed abnormally phosphorylated tau at Thr181
(pThr181) and observed a nearly 60% decrease in the
pThr181 accumulation in Tg[HuC::hTauP301L;DsRed] em-
bryos (n = 300) following either morpholino-mediated zeb-
raﬁsh hs3st2 inactivation, or treatment with LiCl, an
inhibitor of tau phosphorylation used as control treatment
(Supplementary Fig. 7E). Using ﬂuorescence microscopy we
quantiﬁed the accumulation of abnormally phosphorylated
tau with antibodies AT270, AT180 (pThr231/pSer235),
and AT8 in brains of 5 dpf Tg[HuC::hTauP301L;DsRed]
larvae injected or not with MO-hs3st2SPL (n = 150). We
observed a signiﬁcant ﬂuorescence decrease in all the
assayed sites in the brain in zebraﬁsh hs3st2 depleted em-
bryos (n = 150) (Fig. 5). Accordingly, we observed a strong
decreased accumulation of AT270, AT180, PHF1, and AT8
epitopes (Fig. 6) and of the conformational antibody MC1
(Supplementary Fig. 8) in the spinal cord neurons of the 2
dpf zebraﬁsh hs3st2-depleted Tg[HuC::hTauP301L;DsRed]
larvae injected with MO-sh3st2SPL (n = 150). These results
conﬁrm that 3-O-sulphated heparan sulphates play a key
role in abnormal phosphorylation of tau in tauopathy
in vivo.
Hs3st2 depletion rescues TauP301L
induced functional defects
Because 2 dpf Tg[HuC::hTauP301L;DsRed] larvae display
reduced motor neuronal axon branching and elongation
and, as a likely consequence, an impaired escape response
to touch stimuli (Paquet et al., 2009), this line provides us
with a tool to further investigate in vivo the relationship
between 3-O-sulphated heparan sulphates, tau abnormal
phosphorylation and neuronal pathophysiology. First, we
analysed motor neuronal axon morphology using the anti-
syt1, antibody that speciﬁcally recognizes synaptotagmin
1, a synaptic protein expressed in primary motor neurons
(Trevarrow et al., 1990; Fox and Sanes, 2007). As previ-
ously described (Paquet et al., 2009), we observed that
motor neuronal axons were morphologically altered in
the Tg[HuC::hTauP301L;DsRed] embryos, whereas morph-
ology was partially recovered after zebraﬁsh hs3st2 deple-
tion (Fig. 7A). We then measured the length of
outgrowing axons of the four caudal primary motor
neurons immediately anterior to the end of the yolk
extension. As expected, the mean length of motor
neuronal axons was markedly reduced in 48 hpf
Tg[HuC::hTauP301L;DsRed] embryos when compared to
that observed in their non-transgenic siblings (Paquet
et al., 2009) However, after zebraﬁsh hs3st2 depletion,
the mean length of motor neuronal axons was signiﬁcantly
increased in Tg[HuC::hTauP301L;DsRed] embryos to
nearly normal length (n = 25; P50.005) (Fig. 7B). We
next sought to investigate whether zebraﬁsh hs3st2 deple-
tion can rescue, at least partially, the motility defects
observed in Tg[HuC::hTauP301L;DsRed] zebraﬁsh larvae
(Paquet et al., 2009). Following injection of 1.5mM
MO-hs3st2SPL, the escape response to touch stimulus in
Tg[HuC::hTauP301L;DsRed] larvae was signiﬁcantly
increased to near levels measured in non-transgenic sib-
lings (n = 150; P5 0.005) (Fig. 7C). Collectively, these
results provide functional evidence supporting the essen-
tial involvement of 3-O-sulphated heparan sulphates in
tau neuropathology in vivo.
Discussion
We show that HS3ST2 is overexpressed in the hippocam-
pus of patients with Alzheimer’s disease and that intracel-
lular 3-O-sulphated heparan sulphates are critical for the
abnormal phosphorylation of both wild-type tau and tau
carrying the P301L mutation in cells and in a zebraﬁsh
model of tauopathy. Although the occurrence of the intra-
cellular accumulation of heparan sulphates long before the
development of the tau pathology was known in neurons of
patients with Alzheimer’s disease and those with Down’s
syndrome for several years (Snow et al., 1990; Goedert
et al., 1996), the mechanisms, biological signiﬁcance, and
pathophysiological consequences of this event remain un-
known. Similarly, although HS3ST2 expression occurs in
neurons of brain regions vulnerable to Alzheimer’s disease,
the involvement of neuronal 3-O-sulphated heparan sul-
phates and of their 3-O-sulphotransferase synthetizing en-
zymes in the mechanisms leading to tau pathology had
never been investigated. Here, we show that under path-
ology-associated conditions, such as hTauP301L expression
or oxidative stress, membrane-associated heparan sulphate
uptake occurs concomitantly with tau hyperphosphoryla-
tion, delineating a link between membrane biology,
heparan sulphate biology, and tau pathology. This link is
supported by several observations associating HSPG with
altered-membrane biology in Alzheimer’s disease, for in-
stance: (i) the intracellular co-staining of membrane-asso-
ciated HSPG, but not of secreted HSPGs, with
neuroﬁbrillary tangles in Alzheimer’s disease (van Horssen
et al., 2003); (ii) the heparan sulphate-dependent endocyto-
sis of amyloid-b oligomers (Sandwall et al., 2010), tau ﬁ-
brils (Holmes et al., 2013), apolipoprotein-E (Wilsie et al.,
2006), and other proteins for which heparan sulphates are
cell-surface endocytic receptors (Christianson and Belting,
2014); (iii) the relevance in lipid rafts of HSPG, which act
as molecular mediators of raft-dependent endocytosis
(Chen and Williams, 2013); (iv) the heparan sulphates cap-
acity to interact and regulate the activity of membrane-
associated enzymes involved in Alzheimer’s disease such
as the raftophilic b-secretase (Patey et al., 2006).
Moreover, the 3-O-sulphated heparan sulphates require-
ment for HSV1 uptake by neuronal cells (O’Donnell
et al., 2006; Antoine et al., 2014) supports the existence
of the proposed synergy between HSV1 infection and
Alzheimer’s disease pathology (Carter, 2008). Finally, the
central importance of an altered neuronal membrane biol-
ogy in Alzheimer’s disease (Williamson and Sutherland,
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Figure 5 Hs3st2-mediated HSPG sulphation is required for abnormal phosphorylation of tau in zebrafish brain. Double
immunostaining for total tau (red) and phosphorylated tau (green) at residues AT270 (A1-A2”), AT180 (B1-B2”), and AT8 (C1-C2”) in 5 dpf
dissected brains from Tg[HuC::hTauP301L] (Hu::Tau) embryos following morpholino-mediated depletion of zebrafish hs3st2 (Hu::Tau + MO-
hs3st2) (n = 150). Scale bar = 50 mm. The percentage of cells expressing phospho-tau epitopes recognized by antibodies AT270 (left), AT180
(middle) and AT8 (right) compared to cells immunolabelled for total tau is shown (n = 150).
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Figure 6 HS3ST2-mediated sulphation of heparan sulphates is required for the pathological phosphorylation of tau in spinal
cord neurons in zebra fish. (A) Double immunostaining for total tau (red) and abnormally phosphorylated tau (green) with anti-tau antibodies
AT180, AT270, PHF1, and AT8 in spinal cord neurons of Tg[HuC::hTauP301L] (Hu::Tau) embryos following morpholino-mediated depletion of
zebrafish hs3st2 (Hu::Tau + MO-hs3st2). (B) Immunostaining quantification of antibodies AT180, AT270, PHF1, and AT8 signals in spinal cord
neurons. Panels in A represent observations (n = 150) of 5 dpf larvae from two independent experiments. Panels in B represents means of
fluorescence analyses on 150 larvae; error bars show SEM. Scale bar = 50 mm.
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2011) is strongly supported by the striking observation that
most, if not all, Alzheimer’s disease associated loci identiﬁed
by genome-wide association studies (GWAS) including
ABCA7, MS4A6A/MS4A4E, EPHA1, CD33, CD2AP, CLU,
PICALM, CR1, BIN1, and SNORA7A (Hollingworth et al.,
2011), are most of them, as APP, PSEN1, and PSEN2, genetic
variants of membrane-associated proteins. Whether these
genetic variants, as well as an altered tau biology (Stamer
et al, 2002; Ke et al, 2012), can provoke cell-membrane
alterations allowing increased heparan sulphate intern-
alization, are important points that remain to be explored.
Concerning the implication of intracellular heparan
sulphates in the molecular mechanisms leading to the ab-
normal phosphorylation of tau, our data suggest that the
3-O-sulphated glycosaminoglycans bind to tau in a molecu-
lar chaperon-like manner allowing the tau abnormal phos-
phorylation. This hypothesis is supported by previous 1H
NMR (proton nuclear magnetic resonance) and biochem-
ical cross-linking studies showing that heparin readily in-
duces conformational changes in tau allowing the access of
different kinases to epitopes otherwise inaccessible for
phosphorylation (Paudel and Li, 1999; Sibille et al.,
2006), and further supported by our immunostaining,
FRET and phosphorylation data, as well as by the intra-
cellular accumulation of heparan sulphates observed previ-
ous to the apparition of the tau pathology in neuronal cells
of Alzheimer’s disease and Down’s syndrome (Snow el al.,
1990; Goedert et al., 1996). Furthermore, as the 3-O-
sulphated heparan sulphates prompt the abnormal phos-
phorylation of both tau and tauP301L, the enhanced effect
observed on tauP301L could be associated with the presence
of the tau mutation (Alonso Adel et al., 2004). Thus, the
higher susceptibility of tauP301L to undergo heparin-dependent
abnormal phosphorylation can explain the effect of inhibiting
HS3ST2 expression in SH/hTauP301L cells and of hs3st2 in
Tg[HuC::hTauP301L; DsRed] zebraﬁsh embryos, in which the
levels of hs3st2 transcripts were found unchanged compared
to those observed in control embryo (not shown).
Whether the central role of the abnormal phosphoryl-
ation of tau in the Alzheimer’s disease neurodegenerative
process is still controverted, the possibility of a correlation
between genetic variability in membrane associated-pro-
teins, or between altered tau biology, with heparan sul-
phate internalization and interaction with tau, requires to
be considered. This additionally raises questions concerning
the intracellular association of different species of glycosa-
minoglycans with other intracellular heparin-binding pro-
teins, such as -synuclein and superoxide dismutase,
proteins involved in important neurodegenerative diseases.
Indeed, as for neuroﬁbrillary tangles, sulphated glycosami-
noglycans generally co-localize with amyloidosis lesions,
including -synucleinopathies and prion diseases (Zhang
and Li, 2010), suggesting the existence of common events
in the mechanisms involving the sulphated sugars in pro-
teinopathies. In conclusion, our results position intracellu-
lar 3-O-sulphated heparan sulphates, and the enzymes
responsible of their high sulphation in neurons, as central
modulators of tau abnormal phosphorylation before it
occurs. This opens a wide area of research in the ﬁeld of
glyco-neurobiology, positioning HS3ST2 and its products
as potential key players in the development and evolution
of the tau pathology, with the therapeutic consequences
that this implies.
Figure 7 Partial depletion of zebrafish hs3st2 rescues both motor neuron axon outgrowth defects and behavioural abnorm-
alities in Tg[HuC::hTauP301L] embryos. (A) Spinal cord neurons lateral views in yolk extensions, visualized by anti-Syt1, in wild-type
embryos (Control), in Tg[HuC::hTauP301L] embryos that express the hTauP301L mutation (Hu::tau), and in Tg[HuC::hTauP301L] embryos injected
with MO-hs3st2 (Hu::tau + MO-hs3st2). (B) Motor neuronal axons length mean (n = 25) in control wild-type embryos (WT), in
Tg[HuC::hTauP301L] embryos (Hu::Tau), and in Tg[HuC::hTauP301L] embryos following depletion of hs3st2 (Hu::Tau + MO-hs3st2). (C) Motor
response to touching stimuli determined by the percentage of responding larvae in Tg[HuC::hTauP301L] embryos (Hu::Tau) and in
Tg[HuC::hTauP301L] embryos following depletion of hs3st2 (Hu::Tau + MO-hs3st2) (n = 150); error bars show SEM.
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